Compare Petróleo Brasileiro SA (PBR) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs Pfizer Inc — how do they compare? Petróleo Brasileiro SA trades at $24.69 (market cap $149.03B), while Pfizer Inc trades at $27.75 (market cap $159.59B). The key difference: Petróleo Brasileiro SA and Pfizer Inc are close in size by market cap, and Petróleo Brasileiro SA pays the higher dividend (6.98%). Which is the better fit depends on your goals — on Pluang, investors hold Petróleo Brasileiro SA for 25 Days and Pfizer Inc for 158 Days on average.
| PBR | PFE | |
|---|---|---|
Market Cap | $149.03B | $159.59B |
Volume | 30,322,411 | 30,937,010 |
Sector | Energy | Health |
52-Week High | $24.69 | $29.02 |
52-Week Low | $11.54 | $23.67 |
Typical Hold Time | 25 Days | 158 Days |
Enterprise Value | $209.45B | $211.09B |
Dividend Yield | 6.98% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Petrobras (PBR) trades at $23.99, up 0.8% with strong bullish technical signals from moving averages. The company shows robust fundamentals with a P/E of 6.06, net income margin of 24.52%, and ROE of 30.77%. Recent Q2 2026 earnings beat expectations at $1.62 EPS versus $1.52 expected. Positive developments include new oil discoveries and platform deployments boosting production capacity.
PBR presents compelling value with attractive valuation metrics and strong profitability, though current price sits near analyst consensus target of $22.33. Key risks include political interference in Brazil and capital expenditure pressures. The stock offers dividend yield potential with recent $0.53 dividend declaration, supported by 50% analyst buy ratings.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
